Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 13

56P - Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)

Date

10 Sep 2022

Session

Poster session 13

Topics

Immunotherapy

Tumour Site

Hepatobiliary Cancers

Presenters

Do-Youn Oh

Citation

Annals of Oncology (2022) 33 (suppl_7): S19-S26. 10.1016/annonc/annonc1036

Authors

D. Oh1, A.R. He2, S. Qin3, L. Chen4, T. Okusaka5, A. Vogel6, J.W. Kim7, T. Suksombooncharoen8, M.A. Lee9, M. Kitano10, H.A. Burris11, M. Bouattour12, S. Tanasanvimon13, R.E. Zaucha14, A. Avallone15, J.E. Cundom16, N. Rokutanda17, M. Watras18, G. Cohen17, J.W. Valle19

Author affiliations

  • 1 Division Of Medical Oncology, Department Of Internal Medicine, Seoul National University Hospital, and Cancer Research Institute, Seoul National University College of Medicine, 110-744 - Seoul/KR
  • 2 Medical Onology, Georgetown University, Washington/US
  • 3 Medical Onology, Cancer Center of Nanjing, Jinling Hospital, Nanjing/CN
  • 4 Medical Onology, National Institute of Cancer Research, National Health Research Institutes, Zhunan/TW
  • 5 Department Of Hepatobiliary And Pancreatic Oncology, National Cancer Center Hospital, Tokyo/JP
  • 6 Clinic For Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, Hannover/DE
  • 7 Internal Medicine, Seoul National University Bundang Hospital, Seoul/KR
  • 8 Department Of Internal Medicine, Faculty Of Medicine, Chiang Mai University, Chiang Mai/TH
  • 9 Division Of Medical Oncology, Department Of Internal Medicine, Seoul St. Mary’s Hospital, Catholic University, Seoul/KR
  • 10 Second Department Of Internal Medicine, Wakayama Medical University, Wakayama/JP
  • 11 Tennessee Oncology, Sarah Cannon Research Institute, Nashville/US
  • 12 Medical Onology, AP-HP Hôpital Beaujon, Paris/FR
  • 13 Department Of Internal Medicine, Faculty Of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok/TH
  • 14 Department Of Oncology And Radiotherapy, Medical University of Gdańsk, Gdansk/PL
  • 15 Medical Onology, Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples/IT
  • 16 Oncology Department, Instituto de Investigaciones Metabólicas, Buenos Aires/AR
  • 17 Clinical Research, AstraZeneca, Gaithersburg/US
  • 18 Biostatistics, AstraZeneca, Warsaw/PL
  • 19 Medical Oncology, University of Manchester and the Christie NHS Foundation Trust, Manchester/GB
More

Abstract 56P

Background

Advanced BTC is a rare, heterogenous cancer with poor prognosis. At the preplanned interim analysis (data cutoff 11 August 2021) of TOPAZ-1 (NCT03875235), D + GC significantly improved OS versus PBO + GC in pts with advanced BTC (hazard ratio [HR], 0.80; 95% confidence interval [CI], 0.66–0.97; p=0.021). We report an updated OS and safety analysis for TOPAZ-1.

Methods

Pts previously untreated for unresectable locally advanced, recurrent, or metastatic BTC were randomised 1:1 to receive D (1500 mg every 3 weeks [Q3W]) or PBO, + G (1000 mg/m2) and C (25 mg/m2) on days 1 and 8 Q3W, for up to 8 cycles, followed by D (1500 mg Q4W) or PBO monotherapy until disease progression or unacceptable toxicity. The primary objective was to assess OS. This OS and safety analysis was conducted after 6 months (mo) of additional follow-up with 76.9% overall OS event maturity.

Results

At data cutoff (25 February 2022), 685 pts were randomised to D + GC (n=341) or PBO + GC (n=344); median (95% CI) follow-up time was 23.4 (20.6–25.2) mo and 22.4 (21.4–23.8) mo, respectively. Median (95% CI) OS was 12.9 (11.6–14.1) mo with D + GC and 11.3 (10.1–12.5) mo with PBO + GC (HR, 0.76; 95% CI, 0.64–0.91). OS HRs (95% CI) favoured D + GC in all prespecified subgroups, including disease status (initially unresectable, 0.79 [0.65–0.95]; recurrent, 0.76 [0.49–1.20]), primary tumour location (intrahepatic cholangiocarcinoma, 0.78 [0.62–0.99]; extrahepatic cholangiocarcinoma, 0.61 [0.41–0.91]; gallbladder cancer, 0.90 [0.64–1.25]) and PD-L1 (tumour area positivity [TAP] ≥1%, 0.75 [0.60–0.93]; TAP <1%, 0.79 [0.58–1.09]). OS rates (D + GC vs PBO + GC) at 12 mo, 18 mo and 24 mo were 54.3% vs 47.1%, 34.8% vs 24.1% and 23.6% vs 11.5%, respectively. Grade 3/4 treatment-related adverse events (TRAEs) occurred in 60.9% of pts receiving D and 63.5% of pts receiving PBO; TRAEs leading to discontinuation of any study medication occurred in 8.9% and 11.4% of pts, respectively.

Conclusions

D + GC continues to demonstrate clinically meaningful benefit vs PBO, that is consistent among subgroups, and manageable safety with longer follow-up, further supporting D + GC as a new first-line standard of care regimen for pts with advanced BTC.

Clinical trial identification

NCT03875235.

Editorial acknowledgement

Medical writing support, under the direction of the authors, was provided by Brian Woolums, PhD, of CMC Connect, McCann Health Medical Communications, with funding from AstraZeneca, in accordance with Good Publications Practice (GPP3) guidelines.

Legal entity responsible for the study

AstraZeneca.

Funding

AstraZeneca.

Disclosure

D. Oh: Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis, Genentech/Roche, Merck Serono, Bayer, Taiho, ASLAN, Halozyme, Zymeworks, BMS/Celgene, BeiGene, Basilea, Turning Point, Yuhan, Arcus Biosciences, IQVIA; Financial Interests, Institutional, Research Grant: AstraZeneca, Novartis, Array, Eli Lilly, Servier, BeiGene, MSD, Handok. A.R. He: Other, Personal, Advisory Board, Advisory Board meeting on management of biliary cancer and HCC: AstraZeneca. L. Chen: Financial Interests, Personal, Invited Speaker: PharmaEngine (TW), ONO, BMS, Eli Lilly, Ipsen, Novartis, TTY (TW), C-Stone (TW); Financial Interests, Personal, Other, Medical Monitoring for clinical trial.: Taivex (TW); Financial Interests, Personal, Other, DSMC member for clinical trials.: OBI (TW); Financial Interests, Personal, Advisory Board: MSD, AstraZeneca, SynCore (TW); Financial Interests, Personal, Full or part-time Employment, Co-affiliated, Distinguished Investigator and Senior Physician Staff: National Institute of Cancer Research, National Health Research Institutes, Taiwan; Financial Interests, Personal, Full or part-time Employment, Professor of Internal Medicine: Kaohsiung Medical Univrsity Hopsital, Kaohsiung Medical University, Kaohsiung, Taiwan; Financial Interests, Personal, Invited Speaker, Independent Director: ScinoPharm Taiwan, Ltd.; Financial Interests, Personal, Invited Speaker, Alpha-enolase specific antibodies: HuniLife Biotechnology, Inc., Taiwan; Financial Interests, Personal, Invited Speaker, TOPAZ-1, phase III trial: AstraZeneca; Financial Interests, Personal, Invited Speaker, ATTRACTIONs trials, ATT-2 (3L), ATT-4 (1L), ATT-5 (Adjuvant) and ATT-6 (1L).: ONO; Financial Interests, Personal, Invited Speaker, SynCore CT4006, phase 3 trial: Syncore BioPharma, Taiwan; Financial Interests, Institutional, Invited Speaker, Research funding and study medication for TCOG IIT.: Celgene; Financial Interests, Institutional, Invited Speaker, Industry-sponsored, phase II bridging trial in TCOG.: TTY, Taiwan; Non-Financial Interests, Principal Investigator, Investigator-initiated trials: Taiwan Cooperative Oncology Group, National Institute of Cancer Research, Taiwan; Non-Financial Interests, Invited Speaker, Managing Director: Taiwan Oncology Society, taiwan; Non-Financial Interests, Leadership Role, President (2021.09 ∼): Taiwan NeuroEndocrine Tumor Society (TNETS); Non-Financial Interests, Invited Speaker: Taiwan Pancreas Society, Taiwan; Non-Financial Interests, Institutional, Product Samples, Medication support for TCOG trial.: Syncore BioPharma, Taiwan; Non-Financial Interests, Institutional, Product Samples, Medication for TCOG trials.: TTY; Non-Financial Interests, Institutional, Product Samples, Targeted Cancer Panel NGS testing.: ACTgenomics (TW). T. Okusaka: Financial Interests, Personal, Advisory Board: Taiho Pharmaceutical, Daiichi-sankyo, Dainippon Sumitomo Pharma, Eisai, Nihon Servier, Eli lilly, AstraZeneca, Meiji Seika Pharma, Incyte, Takara Bio, Nippon Shinyaku, Pfizer, Mundipharma; Financial Interests, Personal, Invited Speaker: MSD, AstraZeneca, Eisai, Ono Pharmaceutical, Yakut Honsha, Taiho Pharmaceutical, Chugai Pharma, Teijin Pharma, Eli lilly, Nihon Servier, Bayer, Bristol-Myers Squibb, AstraZeneca; Financial Interests, Institutional, Invited Speaker: AstraZeneca, Chugai Pharma, Eisai, Novartis, Bristol-Myers Squibb, MSD, Baxter, Taiho Pharmaceutical, Dainippon Sumitomo Pharma. A. Vogel: Financial Interests, Personal, Invited Speaker: Roche, BMS, MSD, Novartis, EISAI, IPSEN, INCYTE, PierreFabre, Lilly, Imaging Equipment Ltd (AAA), Roche, MSD, Beigene, Jiangsu Hengrui Medicines.; Financial Interests, Personal, Advisory Board: Roche, Bayer, BMS, MSD, EISAI, Ipsen, Incyte, PierreFabre, Lilly, AstraZeneca, Boston Scientific, Sirtex, Daichi-Sankyo. J.W. Kim: Other, Personal, Research Grant: Inno.N, Jeil Pharm; Other, Personal, Other, Consulting fees: AstraZeneca, BeiGene, Beyond Bio, Bristol Myers Squibb/Celgene, Eisai, GC Cell, MSD ONO, Sanofi-Aventis, Servier, and TCUBEit. T. Suksombooncharoen: Financial Interests, Personal, Invited Speaker: AstraZeneca, Novartis, Bayer, Bristol Myers Squibb, baxter, MUNDIPHARMA (THAILAND), Roche, Eli Lilly, Takeda, MSD, Amgen, Janssen; Financial Interests, Personal, Advisory Board: Roche, Novartis; Non-Financial Interests, Principal Investigator: AstraZeneca, Novartis, Roche, MSD. M. Kitano: Other, Institutional, Research Grant: Takeda Pharmaceutical, AbbVie; Other, Personal, Other, Honoraria: EA Pharma. H.A. Burris: Financial Interests, Institutional, Other, Research Grant for work as PI: AbbVie, Agios, ARMO Biosciences, Array BipPharma, AstraZeneca, Bayer, BeiGene, BioAtla, BioMed Valley Discoveries, Boehringer Ingelheim, Bristol-Myers Squibb, CALGB, CicloMed, eFFECTOR Therapeutics, Lilly, EMD Serono, Roche/Genentech, GlaxoSmithKline, H; Financial Interests, Institutional, Other, Uncompensated Consulting: AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, GRAIL, Incyte, Novartis, TG Therapeutics, Vincerx Pharma; Financial Interests, Personal, Stocks/Shares: HCA Healthcare. M. Bouattour: Financial Interests, Personal, Other, Consulting fees: Bayer, Ipsen, Roche, AstraZeneca, Eisai, MSD, BMS, Sirtex Medical; Financial Interests, Personal, Speaker’s Bureau: Eisai, Bayer, Roche; Financial Interests, Personal, Other, Support for attending meetings and/or travel: AstraZeneca, Bayer, Sirtex Medical. S. Tanasanvimon: Other, Personal, Other, Honoraria: AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, MSD, Roche, Novartis. R.E. Zaucha: Financial Interests, Personal, Invited Speaker: BMS, Novartis, Ipsen; Non-Financial Interests, Principal Investigator: BMS, AstraZeneca, Ipsen, Roche, Janssen. A. Avallone: Other, Institutional, Research Grant: Amgen, Bayer, Bristol-Myers; Other, Personal, Advisory Board: MSD, Amgen, Eisai, AstraZeneca. J.E. Cundom: Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim, AstraZeneca, Takeda, Roche. N. Rokutanda: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. M. Watras: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. G. Cohen: Financial Interests, Personal, Full or part-time Employment, I am a full time employee of AstraZeneca. Position is Global Clinical Lead in Immuno-oncology: AstraZeneca; Financial Interests, Personal, Stocks/Shares, Own stock in the company as an employee.: AstraZeneca. J.W. Valle: Financial Interests, Personal, Advisory Board: AstraZeneca, Agios, QED, NuCana BioMed, Servier, Image Equipment Ltd (AAA), Hutchinson Medipharma, Zymeworks, Sirtex, Baxter, Autem, Hutchinson Medipharma; Financial Interests, Personal, Invited Speaker: Ipsen, Mylan, Incyte; Financial Interests, Institutional, Research Grant, Grant funding for ABC-12 study: AstraZeneca; Financial Interests, Institutional, Research Grant, University of Manchester: RedX. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.